课题基金 / 基金详情

Combining Camu-Camu prebiotics and anti-programmed cell death protein-1 to improve gut microbiome and clinical outcomes for patients with non-small cell lung cancer

Combining Camu-Camu prebiotics and anti-programmed cell death protein-1 to improve gut microbiome and clinical outcomes for patients with non-small cell lung cancer
结合 Camu-Camu 益生元和抗程序性细胞死亡蛋白-1，改善非小细胞肺癌患者的肠道微生物组和临床结果
批准号：
466902
负责人：
Lynn Matthew J
金额：
$1.27万
依托单位：
Universit de Montral
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-12-01 至 2022-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466902&lang=en
关键词：
Anti-Pd-1 Avatar Mice Models Cancer Immunology Cancer-Microbiome Gut Microbiome Immune Checkpoint Inhibitors Lung Cancer Therapy Metagenomics Non-Small Cell Lung Cancer Prebiotics

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lung cancer is the most diagnosed cancer and the leading cause of cancer deaths in Canada. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers, but primary response rates to immune checkpoint inhibitors (ICI), specifically anti-programmed-
期刊论文(0)
专著(0)
科研奖励(0)
会议论文